Adverse effects of meglumine antimoniate treatment in dogs with leishmaniosis

Meglumine antimoniate is used to treat canine leishmaniosis. In humans, it has been associated with pancreatitis. Although a few case reports have described acute pancreatitis secondary to antimonial treatment in dogs, some studies have concluded that pancreatitis is not an adverse effect of this medication. The aim of this prospective, observational, longitudinal, and multicentric study was to evaluate whether treatment with meglumine antimoniate could induce pancreatitis in dogs with leishmaniosis. The research was conducted from April 2021 through February 2023 at different hospitals in Spain. Each dog was classified into one of four clinical stages at diagnosis based on clinical signs, ...

To read the full article you must log in with your EGO codes.

Use your EGO login data to access Vet.Journal

Username

Password Show Password

Remember Me

Sign in with a passkey

Log in

• Forgot your password?
• Forgot your username?

Check who can access Vet.Journal